文献速递临床免疫质量管理与危急值

2018年胰岛自身抗体标准化项目:谷氨酸脱羧酶自身抗体检测性能的实验室间比较

Islet Autoantibody Standardization Program 2018 Workshop: Interlaboratory Comparison of Glutamic Acid Decarboxylase Autoantibody Assay Performance.
PubMed 文献 · Clin Chem · 2019-08-13

国际胰岛自身抗体标准化项目(IASP)于2018年5月向参与者分发43例新发1型糖尿病(T1D)患者、7例多种自身抗体阳性非糖尿病个体和90名献血者的血清,集中分析谷氨酸脱羧酶自身抗体(GADA)检测的灵敏度、特异度、ROC-AUC等指标。多数表现最佳的GADA免疫分析方法为非放射性检测,性能与放射结合分析相当或更优。

要点

  • 所有GADA方法中位ROC-AUC为0.87(IQR 0.83-0.89),pAUC95差异大(范围0.001-0.0411)。
  • 广泛采用的桥式ELISA中位pAUC95最佳(0.039;范围0.036-0.041)。
  • 多数表现最佳的GADA方法为非放射性检测,性能不劣于放射结合分析。

核心结论

  • 2018年IASP研讨会上多种新型GADA检测方法性能异质,多数表现最佳的方法为非放射性检测,性能与放射结合分析相当或更优。

研究设计与样本

  • IASP于2018年5月向参与者分发43例新发T1D患者、7例多种自身抗体阳性非糖尿病个体和90名献血者的编码血清,集中收集并分析结果。

主要发现

  • 所有方法的中位ROC-AUC为0.87(IQR 0.83-0.89),中位pAUC95为0.036(IQR 0.032-0.039)。
  • 不同方法间pAUC95差异大(范围0.001-0.0411)。
  • 广泛采用的形式中,桥式ELISA的中位pAUC95最佳(0.039;范围0.036-0.041)。

关键数值与推荐

  • 所有GADA方法中位ROC-AUC为0.87(IQR 0.83-0.89),中位pAUC95为0.036(IQR 0.032-0.039)。
  • 桥式ELISA中位pAUC95为0.039(范围0.036-0.041)。

临床怎么用

  • 临床实验室选择GADA检测方法时可参考IASP性能数据,优先考虑表现与非放射性检测相当或更优的方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Islet Autoantibody Standardization Program (IASP) aims to improve the performance of immunoassays measuring type 1 diabetes (T1D)-associated autoantibodies and the concordance of results among laboratories. IASP organizes international interlaboratory assay comparison studies in which blinded serum samples are distributed to participating laboratories, followed by centralized collection and analysis of results, providing participants with an unbiased comparative assessment. In this report, we describe the results of glutamic acid decarboxylase autoantibody (GADA) assays presented in the IASP 2018 workshop. METHODS: In May 2018, IASP distributed to participants uniquely coded sera from 43 new-onset T1D patients, 7 multiple autoantibody-positive nondiabetic individuals, and 90 blood donors. Results were analyzed for the following metrics: sensitivity, specificity, accuracy, area under the ROC curve (ROC-AUC), partial ROC-AUC at 95% specificity (pAUC95), and concordance of qualitative and quantitative results. RESULTS: Thirty-seven laboratories submitted results from a total of 48 different GADA assays adopting 9 different formats. The median ROC-AUC and pAUC95 of all assays were 0.87 [interquartile range (IQR), 0.83-0.89] and 0.036 (IQR, 0.032-0.039), respectively. Large differences in pAUC95 (range, 0.001-0.0411) were observed across assays. Of formats widely adopted, bridge ELISAs showed the best median pAUC95 (0.039; range, 0.036-0.041). CONCLUSIONS: Several novel assay formats submitted to this study showed heterogeneous performance. In 2018, the majority of the best performing GADA immunoassays consisted of novel or established nonradioactive tests that proved on a par or superior to the radiobinding assay, the previous gold standard assay format for GADA measurement.

来源:Clin Chem,查看原文。版权归原作者所有。

引用

  1. Lampasona V, Pittman DL, Williams AJ, et al. Islet Autoantibody Standardization Program 2018 Workshop: Interlaboratory Comparison of Glutamic Acid Decarboxylase Autoantibody Assay Performance. Clin Chem. 2019. PMID: 31409598. doi:10.1373/clinchem.2019.304196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。